nature portfolio

| Corresponding author(s): | Margo Diricks |
|----------------------------|---------------|
| Last updated by author(s): | 05.07.2022 |

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our <u>Editorial Policies</u> and the <u>Editorial Policy Checklist</u>.

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

| _ | | | | |
|-----|----|----|-----------|------|
| C - | トつ | ±ι | ct | ics |
| · ` | П | | SI | 11 5 |

| n/a | Confirmed |
|-------------|--|
| | $oxed{\boxtimes}$ The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement |
| | 🔀 A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly |
| | The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section. |
| | A description of all covariates tested |
| | 🔀 A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons |
| | A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals) |
| | For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>Give P values as exact values whenever suitable.</i> |
| \boxtimes | For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings |
| \boxtimes | For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes |
| \boxtimes | Estimates of effect sizes (e.g. Cohen's <i>d</i> , Pearson's <i>r</i>), indicating how they were calculated |
| | Our web collection on statistics for biologists contains articles on many of the points above. |

Software and code

Policy information about availability of computer code

Data collection

Genome assemblies were downloaded directly from https://www.ncbi.nlm.nih.gov/assembly. FastQ files were downloaded from SRA using fastq-dump.2.8.2 and GNU parallel v. 20161222

Data analysis

Assemblies were made using shovill v1.1.0, (skesa v2.4.0 + SPAdes v3.15.0; trimmomatic v0.39) or SeqSphere+ v7.7.5. CgMLST scheme creation (cgMLST target definer v1.5) and analysis was performed in SeqSphere+ v7.7.5. Gene extraction was performed in BioNumerics v7.6 and cgSNP analysis with MTBseq v1.0.4. Bash scripts used for this study are available at https://github.com/ngs-fzb/NTMtools, but include only publicly available tools. The cgMLST scheme is publicly available at cgmlst.org (https://www.cgmlst.org/ncs/schema/22602285/).

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.

| $\overline{}$ | | | |
|---------------|---------------|----|---------------|
| ١ | | ١+ | $\overline{}$ |
| • | $\overline{}$ | | $\overline{}$ |

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

| Accession numbers of all whole genome sequencing datasets analyzed in this study are listed in Supplementary Table 1 and 3. The cgMLST scheme is publi |
|--|
| available at cgmlst.org (https://www.cgmlst.org/ncs/schema/22602285/). |
| |

Human research participants

Policy information about studies involving human research participants and Sex and Gender in Research.

| Reporting on sex and gender | No human participants were involved in this study |
|-----------------------------|---|
| Population characteristics | No human participants were involved in this study |
| Recruitment | No human participants were involved in this study |
| Ethics oversight | No human participants were involved in this study |

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Field-specific reporting

| Please select the one below that is the best fit for | value receased If you are not sure | road the appropriate coetion | s bafara making vaur calaction |
|--|------------------------------------|----------------------------------|---------------------------------|
| Please select the one below that is the best fit for | vour research, il vou are not sure | e. read the appropriate sections | s before making your selection. |

| ☑ Life sciences ☐ Behavioural & social sciences ☐ Ecologic | al, evolutionary & environmental sciences |
|--|---|
|--|---|

 $For a \ reference \ copy \ of the \ document \ with \ all \ sections, see \ \underline{nature.com/documents/nr-reporting-summary-flat.pdf}$

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size For this study, we downloaded assemblies (fastA files) from the NCBI/RefSeq Assembly database for 1,797 isolates (Supplementary Table 1) and Illumina paired-end read datasets (fastQ files) from the sequence read archive (SRA) for 372 isolates (Supplementary Table 3). The total dataset (n=2,169) comprised 1991 unique biosamples.

Data exclusions Initially, All assemblies with more than 300 contigs (n=13) were removed from further analysis.

Replication For technical validation, we used same read sets of 30 isolates and created different assemblies with different algorithms. Allele numbers did not differ between these replicates.

Randomization Samples were allocated into experimental groups (e.g. extra-pulmonary vs pulmonary outbreaks) according to the metadata that was

This is not applicable as the associated metadata unambiguously resulted in the allocation of the samples within a specific group.

Behavioural & social sciences study design

All studies must disclose on these points even when the disclosure is negative.

Study description

Blinding

Not applicable

| Research sample | Not applicable |
|-----------------------------|---|
| Sampling strategy | Not applicable |
| Data collection | Not applicable |
| Timing | Not applicable |
| Data exclusions | Not applicable |
| Non-participation | Not applicable |
| Randomization | Not applicable |
| | volutionary & environmental sciences study design these points even when the disclosure is negative. |
| Study description | Not applicable |
| Research sample | Not applicable |
| Sampling strategy | Not applicable |
| Data collection | Not applicable |
| Timing and spatial scale | Not applicable |
| Data exclusions | Not applicable |
| Reproducibility | Not applicable |
| Randomization | Not applicable |
| Blinding | Not applicable |
| Did the study involve field | d work? Yes No |
| Field work, collect | tion and transport |
| Field conditions | Not applicable |
| Location | Not applicable |
| Access & import/export | Not applicable |

Reporting for specific materials, systems and methods

Disturbance

Not applicable

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

| Materials & experime | ntal systems Methods |
|---|---|
| n/a Involved in the study | n/a Involved in the study |
| Antibodies | ChIP-seq |
| Eukaryotic cell lines | |
| Palaeontology and a | |
| Clinical data | |
| Dual use research o | f concern |
| 1 | |
| Antibodies | |
| Antibodies used | Not applicable |
| Validation | Not applicable |
| Eukaryotic cell lin | es es |
| | ell lines and Sex and Gender in Research |
| Cell line source(s) | Not applicable |
| Authentication | Not applicable |
| Mycoplasma contaminati | on Not applicable |
| Commonly misidentified (See ICLAC register) | lines Not applicable |
| (See <u>register)</u> | |
| Palaeontology an | d Archaeology |
| Consideration | Not applicable |
| Specimen provenance | Not applicable |
| Specimen deposition | Not applicable |
| Dating methods | Not applicable |
| Tick this box to confir | m that the raw and calibrated dates are available in the paper or in Supplementary Information. |
| Ethics oversight | Not applicable |
| Note that full information on t | he approval of the study protocol must also be provided in the manuscript. |
| Animals and othe | r research organisms |
| Policy information about <u>st</u> <u>Research</u> | udies involving animals; ARRIVE guidelines recommended for reporting animal research, and Sex and Gender in |
| Laboratory animals | Not applicable |
| Wild animals | Not applicable |
| Reporting on sex | Not applicable |
| Field-collected samples | Not applicable |
| Ethics oversight | Not applicable |

Note that full information on the approval of the study protocol must also be provided in the manuscript.

| Clinical data | |
|--|---|
| Policy information about cli | inical studies |
| , | with the ICMJE guidelines for publication of clinical research and a completed CONSORT checklist must be included with all submissions. |
| Clinical trial registration | Not applicable |
| Study protocol | Not applicable |
| Data collection | Not applicable |
| Outcomes | Not applicable |
| Dual use research | of concern |
| Policy information about du | ual use research of concern |
| Hazards | |
| | berate or reckless misuse of agents or technologies generated in the work, or the application of information presented threat to: |
| No Yes Public health National security Crops and/or livest Ecosystems Any other significa | tock |
| Experiments of concer | 'n |
| Does the work involve an | y of these experiments of concern: |
| No Yes | |
| | to render a vaccine ineffective |
| | to therapeutically useful antibiotics or antiviral agents |
| | nce of a pathogen or render a nonpathogen virulent ibility of a pathogen |
| Alter the host rang | |
| | diagnostic/detection modalities |
| | nization of a biological agent or toxin |
| Any other potentia | lly harmful combination of experiments and agents |
| ChIP-seq | |
| Data deposition | |
| Confirm that both raw | and final processed data have been deposited in a public database such as GEO. |
| Confirm that you have | e deposited or provided access to graph files (e.g. BED files) for the called peaks. |
| Data access links May remain private before public | Not applicable |
| Files in database submiss | ion Not applicable |
| Genome browser session (e.g. <u>UCSC</u>) | Not applicable |

Methodology

Replicates Not applicable Sequencing depth Not applicable

| Antibodies | Not applicab | ole |
|--|----------------------------|--|
| Peak calling parameters | Not applicab | ole |
| Data quality | Not applicab | ole |
| Software | Not applicab | ole |
| Flow Cytometry | | |
| Plots | | |
| Confirm that: | | |
| | | nd fluorochrome used (e.g. CD4-FITC). |
| The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers) All plots are contour plots with outliers or pseudocolor plots. | | |
| | | cells or percentage (with statistics) is provided. |
| Methodology | | |
| Sample preparation | Not | applicable |
| Instrument | | applicable |
| Software | | applicable |
| Cell population abundance | | applicable |
| Gating strategy | | applicable |
| | | ure exemplifying the gating strategy is provided in the Supplementary Information. |
| | | |
| | | |
| Magnetic resonan | nce imag | ging |
| Magnetic resonan | nce imag | ging |
| | nce imag | Not applicable |
| Experimental design | nce imag | |
| Experimental design Design type | | Not applicable |
| Experimental design Design type Design specifications | | Not applicable Not applicable |
| Experimental design Design type Design specifications Behavioral performance n | | Not applicable Not applicable |
| Experimental design Design type Design specifications Behavioral performance in | | Not applicable Not applicable Not applicable |
| Experimental design Design type Design specifications Behavioral performance in Acquisition Imaging type(s) | neasures | Not applicable Not applicable Not applicable Not applicable |
| Experimental design Design type Design specifications Behavioral performance in Acquisition Imaging type(s) Field strength | neasures | Not applicable Not applicable Not applicable Not applicable Not applicable |
| Experimental design Design type Design specifications Behavioral performance in Acquisition Imaging type(s) Field strength Sequence & imaging paral Area of acquisition | neasures | Not applicable Not applicable Not applicable Not applicable Not applicable Not applicable |
| Experimental design Design type Design specifications Behavioral performance in Acquisition Imaging type(s) Field strength Sequence & imaging paral Area of acquisition | neasures meters | Not applicable |
| Experimental design Design type Design specifications Behavioral performance in Acquisition Imaging type(s) Field strength Sequence & imaging paral Area of acquisition Diffusion MRI | measures meters Used | Not applicable |
| Experimental design Design type Design specifications Behavioral performance in Acquisition Imaging type(s) Field strength Sequence & imaging paral Area of acquisition Diffusion MRI | measures meters Used | Not applicable |
| Experimental design Design type Design specifications Behavioral performance in Acquisition Imaging type(s) Field strength Sequence & imaging paral Area of acquisition Diffusion MRI Preprocessing Preprocessing software | measures meters Used Not | Not applicable applicable |
| Experimental design Design type Design specifications Behavioral performance in Acquisition Imaging type(s) Field strength Sequence & imaging paral Area of acquisition Diffusion MRI Preprocessing Preprocessing software Normalization | meters Used Not Not | Not applicable applicable applicable applicable |

Statistical modeling & inference Not applicable Model type and settings Not applicable Effect(s) tested Specify type of analysis: Both Whole brain **ROI-based** Statistic type for inference Not applicable (See Eklund et al. 2016) Not applicable Correction Models & analysis n/a Involved in the study Functional and/or effective connectivity Graph analysis Multivariate modeling or predictive analysis Functional and/or effective connectivity Not applicable

Not applicable

Graph analysis

Multivariate modeling and predictive analysis Not applicable